Qiming U.S. Ventures Management
BELLEVUE, WAfiles as QIMING U.S. VENTURES MANAGEMENT, LLC
$56m in 4 US stocks at the end of 30 September 2025. The top 10 are 100.0% of the money. It changed about 25.8% of the portfolio this quarter.
Value
$56m
Stocks
4
Top 10 share
100.0%
Turnover
25.8%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
- Ventyx Biosciences-100%
- Hillevax-100%
Holdings
- Tourmaline BIO
- Share
- 63.8%
- Value
- $35m
- Shares
- 741,691
Held
- Kezar Life Sciences
- Share
- 0.6%
- Value
- $323,197
- Shares
- 82,871
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Tourmaline BIO | 63.8% | $35m | 741,691 | Held |
| Korro BioKRRO | 31.7% | $18m | 368,085 | Held |
| Jasper TherapeuticsJSPR | 4.0% | $2m | 928,964 | Held |
| Kezar Life Sciences | 0.6% | $323,197 | 82,871 | Held |
Over time and by industry
Value over time
Sep '25
Value is up 135.6% since 30 June 2025.
Where the money is
Health care35.7%
Other64.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.